Clinical trial
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT…
NCT00335335 · GE Healthcare, Industry · Terminated
Key facts
| NCT number | NCT00335335 |
|---|---|
| Title | Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart |
| Official title | Phase 3, Open-label, Multicenter Studies to Determine Efficacy and Safety of VISIPAQUETM (Iodixanol) Injection for Use in Intravenous Contrast-Enhanced CT Angiography of Coronary Arteries |
| Lead sponsor | GE Healthcare, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease |
| Intervention type | Drug |
| Interventions | iodixanol |
| Enrollment | 89 |
| Start date | May 1, 2006 |
| Primary completion | Dec 2, 2006 |
| Completion | Dec 2, 2006 |
| First posted | Jun 9, 2006 |
| Last update posted | Apr 25, 2019 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: